Context: The Ministry of Health and Family Welfare (MoHFW) has notified amendments to the New Drugs and Clinical Trials (NDCT) Rules, 2019 to reduce procedural burdens and promote research-driven pharmaceutical growth. The reforms aim to align India’s regulatory regime with global best practices and enhance the country’s attractiveness as a clinical research hub.

What is CPI?
- Consumer Price Index (CPI) measures short-term changes in retail prices paid by households.
- Published by the National Statistical Office (NSO) as CPI-Rural, CPI-Urban, and CPI-Combined.
- Labour Bureau releases CPI-IW, CPI-AL, CPI-RL for wage indexation.
- Uses the Modified Laspeyres formula with fixed base-year weights.
- CPI-Combined anchors India’s Flexible Inflation Targeting (FIT) under the RBI Act, 1934.
(CPI context is relevant as pharmaceutical pricing and affordability intersect with inflation trends.)
Key Amendments to NDCT Rules
1. Test Licence Waiver
- Small-quantity drug manufacturing for research no longer needs a mandatory test licence.
- Only prior online intimation to CDSCO is required.
- High-risk substances (cytotoxic, narcotic, psychotropic drugs) still need licences.
2. Reduced Timelines
- Processing time for remaining test licence categories cut from 90 days → 45 days.
3. BA/BE Reform
- Bioavailability (BA) and Bioequivalence (BE) studies for low-risk drugs can begin through intimation instead of prior approval.
About NDCT Rules, 2019
- Replaced older provisions under the Drugs and Cosmetics Rules, 1945.
- Administered by Central Drugs Standard Control Organisation (CDSCO) under the Drugs Controller General of India.
- A drug is treated as “new” for four years after first approval.
Significance
- Time Efficiency: Clinical development timelines may shrink by ~90 days.
- Reduced Workload: CDSCO handles 30,000+ test licences and 4,000+ BA/BE applications annually; reforms ease this load.
- Generic Sector Boost: Faster BA/BE initiation strengthens India’s global generic competitiveness.
- Better Risk Focus: Regulators can focus more on high-risk oversight and pharmacovigilance.
- Global Alignment: Moves toward risk-based regulation similar to US FDA/EU frameworks.










